CXCR4 and cancer: Due to the enhanced cellular uptake mediated by T22 targeting CXCR4 and HA targeting CD44 in malignant cells, our delivery vector can target cancer cells as well as CTCs in whole blood to realize efficient genome editing and mRNA detection.